nach oben

International Ophthalmology

Erschienen in:

01.07.2020 | Original Paper

The efficacy and mechanism for action of iguratimod in primary Sjögren’s syndrome patients

verfasst von: Wei Jiang, Lingshu Zhang, Yi Zhao, Xiong He, Chunrong Hu, Yi Liu

Erschienen in: International Ophthalmology | Ausgabe 11/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Primary Sjögren’s syndrome (pSS) has been proven as a systemic autoimmune disorder (such as Sjogren’s syndrome dry eye). This research aimed to evaluate potential treating effects of Iguratimod on pSS.

Methods

Fifty pSS patients were enrolled and randomly divided into Conventional group and Iguratimod group. Improvement in pSS was evaluated every 4 weeks. pSS disease activity was evaluated with European League Against Rheumatism (EULAR) Sjögren’s syndrome disease activity index (ESSDAI). Symptoms were evaluated by determining EULAR Sjögren’s syndrome patient-reported index (ESSPRI), platelet (PLT), IgG and Schirmer I test. Peripheral blood B cell molecules (CD135, IgD, CD38, CD20) and human B cell-activating factor-receptor (BAFF-R) were analyzed with flow cytometry.

Results

After treating for 12-weeks, pSS patients in Iguratimod and Conventional group showed a significant decrease in disease activity (ESSPRI, ESSDAI, PLT, IgG and Schirmer I test) comparing with baselines. Patients’ ESSPRI (2.92 ± 0.19) and disease activity of ESSDAI (4.32 ± 0.29), PLT (95.64 ± 1.86), IgG (13.0 ± 0.45) and Schirmer I test (4.67 ± 0.31) in Iguratimod group were significantly lower compared to Conventional group (4.64 ± 0.15, 5.8 ± 2.08, 77.44 ± 1.41, 16.5 ± 0.44 and 2.25 ± 0.11) (p < 0.0001). Changes of ESSPRI, ESSDAI, PLT, IgG and Schirmer I test were remarkable observed between two groups (p < 0.001). Iguratimod and Conventional treatment demonstrated a significant reduction in total B cells in pSS patients compared with pre-treatment. The pSS patients from Iguratimod and Conventional group showed a significant decreased BAFF-R (61.82 ± 1.52, 74.07 ± 1.11) and CD38⁺IgD⁺ (48.08 ± 0.92, 62.66 ± 1.12) on B cells after treatment compared with baseline (92.26 ± 0.32, 91.53 ± 0.45, 84.39 ± 0.59, 85.04 ± 0.46) (p < 0.001). After treating 12 weeks, BAFF-R, CD38⁺IgD⁺ expression in Iguratimod group decreased significantly compared to Conventional group (p < 0.001).

Conclusions

Iguratimod alleviated symptoms and mediated adaptive-immunity balance by suppressing BAFF-R positive B cell in pSS patients.

Ioannidis JP, Vassiliou VA, Moutsopoulos HM (2002) Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren’s syndrome. Arthritis Rheum 46:741–747CrossRef

Groom J, Kalled SL, Cutler AH et al (2002) Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren’s syndrome. J Clin Invest 109:59–68CrossRef

Ishiguro N, Yamamoto K, Katayama K et al (2013) Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Mod Rheumatol 23:430–439CrossRef

Lu LJ, Teng JL, Bao CD et al (2008) Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial. Chin Med J (Engl) 121:615–619CrossRef

Hara M, Abe T, Sugawara S et al (2007) Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study. Mod Rheumatol 17:1–9CrossRef

Kim CK, Sakudo A, Taniuchi Y et al (2007) Late-onset olfactory deficits and mitral cell loss in mice lacking prion protein with ectopic expression of Doppel. Int J Mol Med 20:169–176PubMed

Lu LJ, Bao CD, Dai M et al (2009) Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate. Arthritis Rheum 61:979–987CrossRef

Aikawa Y, Tanuma N, Shin T et al (1998) A new anti-rheumatic drug, T-614, effectively suppresses the development of autoimmune encephalomyelitis. J Neuroimmunol 89:35–42CrossRef

Tanaka K, Aikawa Y, Kawasaki H et al (1992) Pharmacological studies on 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (T-614), a novel antiinflammatory agent. 4th communication: inhibitory effect on the production of interleukin-1 and interleukin-6. J Pharmacobiodyn 15:649–655CrossRef

10.

Xu Y, Zhu Q, Song J et al (2015) Regulatory effect of Iguratimod on the balance of Th subsets and inhibition of inflammatory cytokines in patients with rheumatoid arthritis. Mediat Inflamm 2015:356040

11.

Tanaka K, Yamamoto T, Aikawa Y et al (2003) Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice. Rheumatology (Oxford) 42:1365–1371CrossRef

12.

Yan Q, Du F, Huang X et al (2014) Prevention of immune nephritis by the small molecular weight immunomodulator iguratimod in MRL/lpr mice. PLoS ONE 9:e108273CrossRef

13.

Vitali C, Bombardieri S, Jonsson R et al (2002) Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554–558CrossRef

14.

Kang YS, Lee HS, Li Y et al (2018) Manifestation of meibomian gland dysfunction in patients with Sjogren’s syndrome, non-Sjogen’s dry eye, and non-dry eye controls. Int Ophthalmol 38:161–1167CrossRef

15.

Yoshioka Y, Takahashi N, Kaneko A et al (2016) Disease activity early in treatment as a predictor of future low disease activity in RA patients treated with iguratimod. Mod Rheumatol 26:169–174CrossRef

16.

Duan XW, Zhang XL, Mao SY et al (2015) Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: a randomized controlled trial. Clin Rheumatol 34:1513–1519CrossRef

17.

Nagashima T, Ishihara M, Shibuya E et al (2017) Three cases of tubulointerstitial nephritis and uveitis syndrome with different clinical manifestation. Int Ophthalmol 37:753–759CrossRef

Titel: The efficacy and mechanism for action of iguratimod in primary Sjögren’s syndrome patients
verfasst von: Wei Jiang
Lingshu Zhang
Yi Zhao
Xiong He
Chunrong Hu
Yi Liu
Publikationsdatum: 01.07.2020
Verlag: Springer Netherlands
Erschienen in: International Ophthalmology / Ausgabe 11/2020
Print ISSN: 0165-5701
Elektronische ISSN: 1573-2630
DOI: https://doi.org/10.1007/s10792-020-01490-6

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Metastasen Leitthema

Orbitale und periokuläre metastatische Tumoren galten früher als sehr selten. Aber mit der ständigen Aktualisierung von Medikamenten und Nachweismethoden für die Krebsbehandlung werden neue Chemotherapien und Strahlenbehandlungen eingesetzt. Die …

Staging und Systemtherapie bei okulären und periokulären Metastasen

Metastasen Leitthema

Metastasen bösartiger Erkrankungen sind die häufigsten Tumoren, die im Auge diagnostiziert werden. Sie treten bei ungefähr 5–10 % der Patienten mit soliden Tumoren im Verlauf der Erkrankung auf. Besonders häufig sind diese beim Mammakarzinom und …

Wundheilung nach Trabekulektomie

Trabekulektomie CME-Artikel

Die überschießende Wundheilung in der filtrierenden Glaukomchirurgie ist ein zentraler Faktor für ein operatives Versagen. Nach der Einführung der Trabekulektomie in den 1960er-Jahren wurden viele Faktoren erkannt, die mit einer vermehrten …

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Metastasen Leitthema

Peri- sowie intraokuläre Metastasen sind insgesamt gesehen selten und meist Zeichen einer fortgeschrittenen primären Tumorerkrankung. Die Therapie ist daher zumeist palliativ und selten kurativ. Zudem ist die Therapiefindung sehr individuell. Die …

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2020

Axial length-related inter-individual variability in the posterior pole morphology of healthy eyes

Central serous chorioretinopathy associated with high-dose follistatin-344: a retrospective case series

Ocular findings in patients with attention deficit and hyperactivity

Premium intraocular lens implantation in eyes with vitrectomy done

Outcomes and complications in scleral-fixated intraocular lens implantations

Posterior uveal melanoma in 321 Asian Indian patients: analysis based on the 8th edition of American Joint Committee Cancer classification

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Staging und Systemtherapie bei okulären und periokulären Metastasen

Wundheilung nach Trabekulektomie

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Update Augenheilkunde